ate phase II study of weekly paclitaxel (BMS-181339) in patients with advanced head and neck cancer
Phase 2
- Conditions
- Head and neck cancer
- Registration Number
- JPRN-jRCT2080220194
- Lead Sponsor
- Bristol-Myers K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
1. Patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy and not suitable for further radical local treatment or patients with distant metastases, and measurable disease(lesion(s) with largest diameter of 10 mm or more). 2. Age range of 20 years and older to less than 75 years. 3. Performance Status : 0 - 2
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy: response rate, duration of observed response Safety: incidence rates and severity of observed adverse events
- Secondary Outcome Measures
Name Time Method